John M. Burke, MD, and Shaji Kumar, MD, discuss practice-changing presentations in lymphomas, CLL, and multiple myeloma from ASCO 2019.
Noopur Raje, MD: Clinical impact of latest data for idecabtagene vicleucel (bb2121) and other CAR T-cells in relapsed/refractory multiple myeloma.
A CME-certified activity with insights on the optimal care of advanced gastric/GEJ cancers using checkpoint inhibitors from Clinical Care Options
This archived CCO symposium Webcast provides expert guidance on the use of immune checkpoint inhibitors in advanced head and neck cancers (HNSCC)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.